Chen Yuan-sheng, Li Li, Cui Fu-qiang, Xing Wen-ge, Wang Lu, Jia Zhi-yuan, Zhou Mai-geng, Gong Xiao-hong, Wang Fu-zhen, Zheng Hui, Luo Hui-ming, Bi Sheng-li, Wang Ning, Yang Wei-zhong, Liang Xiao-feng
Chinese Center for Disease Control and Prevention, Beijing 100050.
Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Sep;32(9):888-91.
To better understand and measure the status of hepatitis C virus (HCV) infection, we conducted a sero-epidemiological study using the remaining blood samples and data of the nationwide survey of hepatitis B in Chinese residents which was carried out in 2006.
The anti-HCV reagent was screened out from the reagents by the HCV infection blood serum plate with anti-HCV positives or negatives. This plate recognized the Murex 3.0 and Ortho 3.0 reagents as gold standards. Anti-HCV in the blood samples were tested using this reagent and confirmed by Chiron HCV RIBA 3.0 reagents.
Among the population aged 1 year to 59 year-olds, the overall prevalence rate of anti-HCV was 0.43% (95%CI: 0.33% - 0.53%), with the rates of anti-HCV among males and females as 0.46% and 0.40%, respectively. The prevalence rate of anti-HCV in urban area was 0.43%, and in rural area it was 0.43%. The prevalence rate of anti-HCV in the Eastern, Middle and Western areas were 0.37% (95%CI: 0.21% - 0.53%), 0.67% (95%CI: 0.40% - 0.94%) and 0.31% (95%CI: 0.20% - 0.42%) respectively. The prevalence rates of anti-HCV for the three areas did not show significant differences, statistically. The prevalence rate of anti-HCV in the South and North areas were 0.29% (95%CI: 0.21% - 0.52%) and 0.53% (95%CI: 0.38% - 0.64%) respectively.
Our data revealed that China was in the low prevalence area for hepatitis C infection and the results also suggested that the comprehensive measures for HCV control and prevention had been successfully achieved in the country.
为了更好地了解和衡量丙型肝炎病毒（HCV）感染状况，我们利用2006年全国居民乙型肝炎调查剩余的血样和数据进行了一项血清流行病学研究。
用含抗-HCV阳性或阴性的HCV感染血清板从试剂中筛选抗-HCV试剂。该平板将Murex 3.0和Ortho 3.0试剂视为金标准。使用该试剂检测血样中的抗-HCV，并通过Chiron HCV RIBA 3.0试剂进行确认。
在1岁至59岁人群中，抗-HCV总体患病率为0.43%（95%可信区间：0.33% - 0.53%），男性和女性的抗-HCV患病率分别为0.46%和0.40%。城市地区抗-HCV患病率为0.43%，农村地区为0.43%。东部、中部和西部地区抗-HCV患病率分别为0.37%（95%可信区间：0.21% - 0.53%）、0.67%（95%可信区间：0.40% - 0.94%）和0.31%（95%可信区间：0.20% - 0.42%）。这三个地区的抗-HCV患病率在统计学上没有显著差异。南部和北部地区抗-HCV患病率分别为0.29%（95%可信区间：0.21% - 0.52%）和0.53%（95%可信区间：0.38% - 0.64%）。
我们的数据显示中国处于丙型肝炎感染低流行地区，结果还表明该国已成功实施了丙型肝炎防控综合措施。
